Xilio Therapeutics Statistics
Total Valuation
XLO has a market cap or net worth of $60.73 million. The enterprise value is -$69.00 million.
| Market Cap | 60.73M |
| Enterprise Value | -69.00M |
Important Dates
The last earnings date was Wednesday, August 12, 2026, before market open.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XLO has 6.58 million shares outstanding. The number of shares has increased by 77.75% in one year.
| Current Share Class | 6.58M |
| Shares Outstanding | 6.58M |
| Shares Change (YoY) | +77.75% |
| Shares Change (QoQ) | +235.57% |
| Owned by Insiders (%) | 8.17% |
| Owned by Institutions (%) | 26.23% |
| Float | 3.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.95 |
| Forward PS | 4.34 |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.25, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.25 |
| Quick Ratio | 4.15 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -55.03% and return on invested capital (ROIC) is -42.07%.
| Return on Equity (ROE) | -55.03% |
| Return on Assets (ROA) | -13.61% |
| Return on Invested Capital (ROIC) | -42.07% |
| Return on Capital Employed (ROCE) | -26.13% |
| Weighted Average Cost of Capital (WACC) | 3.25% |
| Revenue Per Employee | $843,316 |
| Profits Per Employee | -$287,224 |
| Employee Count | 76 |
| Asset Turnover | 0.44 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.65% in the last 52 weeks. The beta is -0.12, so XLO's price volatility has been lower than the market average.
| Beta (5Y) | -0.12 |
| 52-Week Price Change | -0.65% |
| 50-Day Moving Average | 9.01 |
| 200-Day Moving Average | 8.79 |
| Relative Strength Index (RSI) | 53.56 |
| Average Volume (20 Days) | 15,893 |
Short Selling Information
The latest short interest is 425,882, so 6.47% of the outstanding shares have been sold short.
| Short Interest | 425,882 |
| Short Previous Month | 268,180 |
| Short % of Shares Out | 6.47% |
| Short % of Float | 12.52% |
| Short Ratio (days to cover) | 9.36 |
Income Statement
In the last 12 months, XLO had revenue of $64.09 million and -$21.83 million in losses. Loss per share was -$3.32.
| Revenue | 64.09M |
| Gross Profit | 53.30M |
| Operating Income | -31.37M |
| Pretax Income | -21.83M |
| Net Income | -21.83M |
| EBITDA | -30.03M |
| EBIT | -31.37M |
| Loss Per Share | -$3.32 |
Balance Sheet
The company has $136.04 million in cash and $6.30 million in debt, with a net cash position of $129.74 million or $19.72 per share.
| Cash & Cash Equivalents | 136.04M |
| Total Debt | 6.30M |
| Net Cash | 129.74M |
| Net Cash Per Share | $19.72 |
| Equity (Book Value) | 72.26M |
| Book Value Per Share | 10.98 |
| Working Capital | 111.27M |
Cash Flow
In the last 12 months, operating cash flow was -$60.60 million and capital expenditures -$670,000, giving a free cash flow of -$61.27 million.
| Operating Cash Flow | -60.60M |
| Capital Expenditures | -670,000 |
| Depreciation & Amortization | 1.34M |
| Net Borrowing | n/a |
| Free Cash Flow | -61.27M |
| FCF Per Share | -$9.31 |
Margins
Gross margin is 83.16%, with operating and profit margins of -48.94% and -34.06%.
| Gross Margin | 83.16% |
| Operating Margin | -48.94% |
| Pretax Margin | -34.06% |
| Profit Margin | -34.06% |
| EBITDA Margin | -46.85% |
| EBIT Margin | -48.94% |
| FCF Margin | n/a |
Dividends & Yields
XLO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -77.75% |
| Shareholder Yield | -77.75% |
| Earnings Yield | -35.94% |
| FCF Yield | -100.88% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | -47.37% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 16, 2026. It was a reverse split with a ratio of 1:14.
| Last Split Date | Mar 16, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:14 |
Scores
XLO has an Altman Z-Score of -3.03 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.03 |
| Piotroski F-Score | 2 |